Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07BNG
|
|||
| Former ID |
DIB010859
|
|||
| Drug Name |
RHIgM12B7
|
|||
| Synonyms |
SHIgM12; B7-DC-crosslinking recombinant human monoclonal antibody (cancer), Mayo Clinic
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Mayo Foundation
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Programmed cell death protein 2 (PD-2) | Target Info | . | [2] |
| NetPath Pathway | IL2 Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00658892) Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma. U.S. National Institutes of Health. | |||
| REF 2 | National Cancer Institute Drug Dictionary (drug id 593681). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.